A study to evaluate safety and tolerability of QLS-101 in Normal Tension Glaucoma
QC-202 is a randomized, active-controlled multi-site double-masked clinical study to evaluate the safety and tolerability of QLS-101 versus timolol maleate preservative-free (PF) 0.5% ophthalmic solution in patients with normal tension glaucoma (NTG).
About Normal Tension Glaucoma
Normal Tension Glaucoma (NTG) is a form of glaucoma in which damage occurs to the optic nerve over time despite a patient having normal eye pressure called Intraocular Pressure (IOP). Symptoms may include changes to the optic nerve head, including cupping or color changes under examination, and progressive vision loss seen in visual field tests which may not be immediately noticeable to the patient.
Studies have confirmed that higher IOP is still a risk factor for the progression of NTG, which can lead to blindness. Lowering IOP is the only means currently to reduce the risk of glaucoma progression.
QLS-101 is an investigational ATP-sensitive potassium channel opener invented at Mayo Clinic and is being developed under license by Qlaris Bio. QLS-101 is administered as an eyedrops and is believed to lower a unique component of eye pressure, called Episcleral Venous Pressure or EVP in a manner different from typical glaucoma medications.
By lowering EVP, QLS-101 may potentially further reduce IOP in patients with Normal Tension Glaucoma which may lower the risk of progression.
Key Eligibility Criteria
18 years of age or older
Diagnosis of Normal Tension Glaucoma or Low Tension Glaucoma
No historical intraocular pressure ≥ 22 mmHg
This is not a complete list of all eligibility criteria for the QC-202 study with QLS-101. For more information, please visit ClinicalTrials.gov (study identifier NCT04857827) for complete information using the link below.
Key Study Locations
San Francisco, CA
Los Angeles, CA
Sioux Falls, SD
PARTICIPATE IN THE QC-202 STUDY
To participate in the QC-202 study for NTG with QLS-101, please contact the Qlaris Bio clinical team at firstname.lastname@example.org or using the form.
QLS-101 is an investigational drug intended for the lowering of intraocular pressure, including in patients with normal tension glaucoma (NTG). QLS-101 has not yet been approved by any regulatory agency, such as the U.S. Food and Drug Administration (FDA) and its safety and efficacy has not been established. Patients should discuss any participation in a clinical trial with their healthcare provider.